Study Evaluating Ampreloxetine for Neurogenic Orthostatic Hypotension Misses Endpoint
The phase 3 study was evaluating the efficacy and safety of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients 30 years of age and older.
